Status:

COMPLETED

A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)

Lead Sponsor:

Ortho Biotech Products, L.P.

Conditions:

Hepatitis C

Anemia

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

The purpose of this study was to describe the time course and extent of hemoglobin (Hb) changes and the erythropoietic response to PEG-IFN/RBV-induced anemia In HCV-infected subjects.

Detailed Description

Patients receiving combination therapy for chronic hepatitis C virus (HCV) infection (standard or pegylated interferon alfa \[PEG-IFN\] in combination with ribavirin \[RBV\]) frequently develop modera...

Eligibility Criteria

Inclusion

  • Signed Informed Consent
  • HCV- infected patients confirmed by PCR or branched DNA (b-DNA)
  • Scheduled to commence combination RBV/IFN or RBV/PEG-IFN therapy on Day 1
  • Normal serum creatinine
  • Life expectancy \> 6 months

Exclusion

  • HIV-infected patients
  • History of any primary hematologic disease
  • Anemia attributable to factors such as iron or folate deficiency, pre-treatment
  • hemolysis or gastrointestinal bleeding
  • Has suspected or confirmed significant hepatic disease from an etiology other than
  • HCV (e.g. alcohol, HBV, autoimmune disease etc)
  • Current, active substance abuser
  • Pregnant or breast feeding
  • Women of childbearing potential not taking adequate birth control measures
  • Exposure to Epoetin alfa within three (3) months prior to study enrollment or during study
  • Transfusion within three (3) months prior to study entry

Key Trial Info

Start Date :

October 1 2001

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2002

Estimated Enrollment :

105 Patients enrolled

Trial Details

Trial ID

NCT00328549

Start Date

October 1 2001

End Date

December 1 2002

Last Update

May 19 2011

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV) | DecenTrialz